Breaking News Instant updates and real-time market news.

QCOM

Qualcomm

$56.82

-0.11 (-0.19%)

, WOW

WideOpenWest

$17.26

-0.33 (-1.88%)

10:38
06/19/17
06/19
10:38
06/19/17
10:38

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Qualcomm (QCOM) reinstated with a Hold at Deutsche Bank. 2. WideOpenWest (WOW) was initiated with an Outperform at Macquarie, RBC Capital, Credit Suisse, and Evercore ISI, a Strong Buy at Raymond James, as well as a Buy at SunTrust and UBS. 3. Appian (APPN) was initiated with an Outperform at Cowen, an Equal Weight at Morgan Stanley and Barclays, a Sector Weight at Pacific Crest, a Hold at Canaccord, and a Neutral at Goldman Sachs. 4. Smart Global (SGH) was initiated with an Overweight at Barclays, a Strong Buy at Needham, and a Buy at Roth Capital, Stifel, Jefferies, and Deutsche Bank. 5. Credit Suisse (CS) resumed with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

QCOM

Qualcomm

$56.82

-0.11 (-0.19%)

WOW

WideOpenWest

$17.26

-0.33 (-1.88%)

APPN

Appian

$18.22

0.06 (0.33%)

SGH

Smart Global

$15.30

0.15 (0.99%)

CS

Credit Suisse

$14.01

0.465 (3.43%)

  • 22

    Jun

QCOM Qualcomm
$56.82

-0.11 (-0.19%)

05/29/17
RAJA
05/29/17
DOWNGRADE
Target $11
RAJA
Market Perform
BlackBerry downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Steven Li downgraded BlackBerry (BBRY) to Market Perform while raising his price target for the shares to $11 from $9.50. The mobile communications solutions provider closed Friday down 11c to $11.11. The shares are up 42% since the analyst's upgrade to Outperform on August 12, 2016. The final award payment of $940M by Qualcomm (QCOM) boosts an "already strong balance sheet" and may be used for acquisitions, Li tells investors in a research not titled "Tapping the Brakes after Strong Run."
06/15/17
SUSQ
06/15/17
NO CHANGE
Target $67
SUSQ
Positive
Qualcomm price target raised to $67 from $61 at Susquehanna
Susquehanna analyst Christopher Rolland raised his price target on Qualcomm to $67 from $61 following news it entered into a joint venture with JAC Capital, Leadcore, and Wise Road Capital which will be called JLQ Technology and will be launched later this year. He believes this suggest significant implications for Qualcomm as it could help mitigate the long-term competitive threats in the China. Rolland reiterated his Positive rating on Qualcomm shares.
06/19/17
DBAB
06/19/17
DOWNGRADE
Target $110
DBAB
Hold
NXP Semiconductors downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Ross Seymore downgraded NXP Semiconductors (NXPI) to Hold citing the stock's proximity to Qualcomm's (QCOM) all-cash takeout price of $110 per share. He continues to expect the deal to close by the end of 2017 at the announced price. Qualcomm is unlikely to pay a "meaningfully higher price" given the "lack of a viable second bidder," the analyst contends. He has a $110 price target for NXP shares. The chipmaker closed Friday up 9c to $109.09.
06/19/17
DBAB
06/19/17
INITIATION
Target $62
DBAB
Hold
Qualcomm reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Ross Seymore reinstated coverage of Qualcomm (QCOM) with a Hold rating and $62 price target. While the current valuation is "enticing," uncertainty around the timing of the NXP Semiconductors (NXPI) deal closing and questions surrounding litigation with Apple (AAPL) are likely to keep the shares range-bound, the analyst contends.
WOW WideOpenWest
$17.26

-0.33 (-1.88%)

06/19/17
FBCO
06/19/17
INITIATION
Target $20
FBCO
Outperform
WideOpenWest initiated with an Outperform at Credit Suisse
Credit Suisse analyst Omar Sheikh started WideOpenWest with an Outperform rating and $20 price target, citing the growing demand for bandwidth and the company's fiber-rich network.
06/19/17
MACQ
06/19/17
INITIATION
Target $20
MACQ
Outperform
WideOpenWest initiated with an Outperform at Macquarie
Macquarie analyst Amy Yong initiated WideOpenWest with an Outperform and a $20 price target citing edge-out opportunities and a deleveraging balance sheet.
06/19/17
RBCM
06/19/17
INITIATION
RBCM
Outperform
WideOpenWest initiated with an Outperform at RBC Capital
RBC Capital analyst Jonathan Atkin started coverage of WideOpenWest with a $20 price target and an Outperform rating. The analyst says that WideOpenWest's "hyper-local focus in less competitive markets will enable the company to execute profitable network extensions, driving top-line and margin growth." The analyst adds that it should benefit from its "video agnostic" approach which enables it to target viewers of all types of video.
06/19/17
RHCO
06/19/17
INITIATION
RHCO
Buy
WideOpenWest initiated with a Buy at SunTrust
SunTrust analyst Greg Miller started coverage of WideOpenWest with a $24 price target and a Buy rating. The analyst thinks that the company's products enable MSOs to target broadband customers more effectively, and he believes that the company will benefit from its expansion into new markets. The analyst expects the company to report "strong" results and margin increases.
APPN Appian
$18.22

0.06 (0.33%)

06/19/17
PACS
06/19/17
INITIATION
PACS
Sector Weight
Appian initiated with a Sector Weight at Pacific Crest
Pacific Crest analyst Ben McFadden started Appian with a Sector Weight rating saying near-term upside could be limited with the shares up 50% since the IPO.
06/19/17
COWN
06/19/17
INITIATION
Target $21
COWN
Outperform
Appian initiated with an Outperform at Cowen
Cowen analyst Gregg Moskowitz initiated Appian with an Outperform rating, citing the company's impressive low-code and BPM capabilities and the its positioning within the emerging digital transformation trend as customers look to automate data driven processes. Moskowitz has a $21 price target on Appian shares.
06/19/17
MSCO
06/19/17
INITIATION
Target $18
MSCO
Equal Weight
Appian initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Sanjit Singh initiated Appian with an Equal Weight and an $18 price target saying valuation is full.
06/19/17
ADAM
06/19/17
INITIATION
Target $18
ADAM
Hold
Appian initiated with a Hold at Canaccord
Canaccord analyst Richard Davis initiated Appian with a Hold citing its 52% appreciation since its IPO and the inability to justify higher assumptions at current levels. Davis has an $18 price target on Appian shares.
SGH Smart Global
$15.30

0.15 (0.99%)

06/19/17
NEED
06/19/17
INITIATION
Target $20
NEED
Strong Buy
Smart Global initiated with a Strong Buy at Needham
Needham analyst Rajvindra Gill initiated Smart Global with a Strong Buy and a $20 price target.
06/19/17
ROTH
06/19/17
INITIATION
Target $24
ROTH
Buy
Smart Global initiated with a Buy at Roth Capital
Roth Capital analyst Suji Desilva initiated Smart Global Holdings with a Buy rating and a $24 price target, saying he is encouraged by the company's growth and share expansion opportunity as well as its differentiated specialty memory offering.
06/19/17
JEFF
06/19/17
INITIATION
Target $21
JEFF
Buy
Smart Global initiated with a Buy at Jefferies
Jefferies analyst Mark Lipacis started Smart Global Holdings with a Buy rating and $21 price target. The company should benefit from widening memory demand and rising average memory content, the analyst contends.
06/19/17
STFL
06/19/17
INITIATION
STFL
Buy
Smart Global initiated with a Buy at Stifel
Stifel analyst Kevin Cassidy started coverage of Smart Global with a $27 price target and a Buy rating. The analyst says that the company's Specialty Memory unit is "poised to benefit from the increased importance of memory in the datacenter architecture." He also expects the company to benefit from increased smartphone adoption in Brazil and higher content memory requirements there.
CS Credit Suisse
$14.01

0.465 (3.43%)

06/19/17
DBAB
06/19/17
UPGRADE
DBAB
Buy
Credit Suisse upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Kinner Lakhani upgraded Credit Suisse to Buy with a CHF 15 price target. An inflection in the company's operating results is near following the recent anticipated capital raise, the analyst contends.
06/19/17
BOFA
06/19/17
INITIATION
Target $17.19
BOFA
Buy
Credit Suisse resumed with a Buy at BofA/Merrill
BofA/Merrill analyst Andrew Stimpson resumed coverage on Credit Suisse with a Buy and a $17.20 price target.
06/19/17
06/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Neutral from Sell at UBS with analyst Carter Gould saying he sees an improved risk/reward and a positive near-term setup going into the second quarter earnings call and strategic review. 2. Clovis (CLVS) upgraded to Neutral from Sell at Chardan. 3. Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Christopher Prykull saying early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. 4. Athene Holding (ATH) upgraded to Outperform from Neutral at Credit Suisse with analyst John Nadel saying he believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. 5. Credit Suisse (CS) upgraded to Buy from Hold at Deutsche Bank with analyst Kinner Lakhani saying an inflection in the company's operating results is near following the recent anticipated capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/17/17
02/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Workday (WDAY) upgraded to Overweight from Neutral at Piper Jaffray by analyst Alex Zukin, who said his channel checks indicate the company's fundamentals have improved materially since last quarter. He notes that his checks on Workday and Salesforce (CRM) "came back the strongest in recent memory." 2. Tempur Sealy (TPX) upgraded to Outperform from Market Perform at Raymond James, as analyst Budd Bugatch said all the bad news is known and the improvement in revenues and earnings will become more visible as 2017 unfolds. 3. Capital One (COF) upgraded to Buy from Neutral at Goldman Sachs by analyst Ryan Nash, who raised his price target for the shares to $110 from $106. Almost all of the bank's increases in losses during 2016 can be explained by "growth math," which should have a "finite life to it," Nash tells investors. 4. Credit Suisse (CS) upgraded to Overweight from Equal Weight at Morgan Stanley by analyst Magdalena Stoklosa, who thinks connectivity across businesses, capital utilization, and earnings quality from here will result in more predictable earnings. 5. Chemours (CC) upgraded to Positive at Susquehanna by analyst Don Carson, who sees significant upside he sees to management's modest EBITDA guidance due to greater momentum in TiO2 prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PRGS

Progress Software

$37.49

0.18 (0.48%)

07:47
09/19/17
09/19
07:47
09/19/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Progress Software »

Progress:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGS

Progress Software

$37.49

0.18 (0.48%)

07:47
09/19/17
09/19
07:47
09/19/17
07:47
Hot Stocks
Progress Software 'values' Praesidium's ideas, welcomes input from investors »

In response to a letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

, AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Hot Stocks
Jacobs Engineering selected by Aerie Pharmaceuticals as engineering contractor »

Jacobs Engineering Group…

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 28

    Feb

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

, AXAHY

AXA

$29.47

0.13 (0.44%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Periodicals
BNP weighing tie-up of money-management division with Axa unit, Bloomberg says »

BNP Paribas (BNPQY),…

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

AXAHY

AXA

$29.47

0.13 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFC

Chemical Financial

$49.32

0.71 (1.46%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Downgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSII

Quality Systems

$15.71

-0.14 (-0.88%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Initiation
Quality Systems initiated  »

Quality Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/19/17
09/19
07:45
09/19/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: Risk-on…

HOLI

Hollysys

$20.77

0.42 (2.06%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Conference/Events
Hollysys management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 16

    Oct

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

, AMGN

Amgen

$186.47

-1 (-0.53%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Hot Stocks
Cytokinetics doses first patient in Japan in GALACTIC-HF Phase 3 trial »

Cytokinetics announced…

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

AMGN

Amgen

$186.47

-1 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

KORS

Michael Kors

$44.65

-0.27 (-0.60%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Technical Analysis
Technical View: Michael Kors moves higher, analyst action »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Periodicals
Intel Capital invested over $1B in AI-focused companies, TechCrunch says »

Intel has invested more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 05

    Oct

PDCO

Patterson Companies

$37.94

-0.59 (-1.53%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Initiation
Patterson Companies initiated  »

Patterson Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$179.98

3.28 (1.86%)

, BSTI

BEST Inc

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Syndicate
BEST Inc cuts size of proposed IPO following 'tepid' response, Reuters reports »

Best Inc (BSTI), a…

BABA

Alibaba

$179.98

3.28 (1.86%)

BSTI

BEST Inc

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FOLD

Amicus

$13.67

-0.21 (-1.51%)

07:42
09/19/17
09/19
07:42
09/19/17
07:42
Hot Stocks
Amicus granted FDA Fast Track Designation for migalastat »

Amicus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.73

0.1 (3.80%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Initiation
Rite Aid initiated  »

Rite Aid initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MDGL

Madrigal Pharmaceuticals

$19.80

0.99 (5.26%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Hot Stocks
Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB review »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MDSO

Medidata

$75.85

-0.01 (-0.01%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Initiation
Medidata initiated  »

Medidata initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ABX

Barrick Gold

$16.92

-0.38 (-2.20%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Conference/Events
Barrick Gold management to meet with Deutsche Bank »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Oct

07:40
09/19/17
09/19
07:40
09/19/17
07:40
General news
Treasury Market Outlook: yields are a little lower »

Treasury Market Outlook:…

SFTBF

SoftBank

$78.30

0.3501 (0.45%)

07:39
09/19/17
09/19
07:39
09/19/17
07:39
Periodicals
SoftBank Ventures Korea looks to invest in promising start-ups, CNBC says »

SoftBank Ventures Korea,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$148.42

-1.46 (-0.97%)

07:38
09/19/17
09/19
07:38
09/19/17
07:38
Initiation
McKesson initiated  »

McKesson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

SUPN

Supernus

$49.65

0.6 (1.22%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Downgrade
Supernus rating change  »

Supernus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

HSIC

Henry Schein

$80.90

-1.98 (-2.39%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Initiation
Henry Schein initiated  »

Henry Schein initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$68.34

0.26 (0.38%)

07:36
09/19/17
09/19
07:36
09/19/17
07:36
Recommendations
CarMax analyst commentary  »

CarMax price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

07:36
09/19/17
09/19
07:36
09/19/17
07:36
Periodicals
Portola blood thinner launch could be complicated by guidelines, STAT News says »

The commercial launch of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.